ZBIO (Zenas BioPharma) Current Deferred Taxes Liabilities : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Zenas BioPharma's current deferred tax liabilities for the quarter that ended in Mar. 2025 was $0.00 Mil.

Zenas BioPharma Current Deferred Taxes Liabilities Historical Data

The historical data trend for Zenas BioPharma's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Current Deferred Taxes Liabilities Chart

Zenas BioPharma Annual Data

Trend

Dec22

Dec23

Dec24

Current Deferred Taxes Liabilities

Zenas BioPharma Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Deferred Taxes Liabilities	Get a 7-Day Free Trial					-	-	-	-	-

Zenas BioPharma Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenas BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Current Deferred Taxes Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

852 Winter Street, Suite 250, Waltham, MA, USA, 02451

Website

https://www.zenasbio.com

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.